Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Safety, Tolerability, and Efficacy Study of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients With Active or Prior Inhibitors
Conditions
Interventions
Valoctocogene roxaparvovec
Locations
9
United States
Children's Hospital Los Angeles
Los Angeles, California, United States
Hemocentro Da UNICAMP
Campinas, Brazil
Arthur De Siqueira Cavalcanti Hematology State Institute
Rio de Janeiro, Brazil
Chaim Sheba Medical Center
Ramat Gan, Israel
Kyung Hee University Hospital at Gangdong
Seoul, South Korea
Kaohsiung Medical University - Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Start Date
December 10, 2020
Primary Completion Date
April 1, 2029
Completion Date
April 1, 2029
Last Updated
July 14, 2025
NCT06312475
NCT03619863
NCT04723693
NCT04303572
NCT04548791
NCT03204539
Lead Sponsor
BioMarin Pharmaceutical
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions